Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: Beneficial effects of the LpPLA2 inhibitor darapladib

Journal of Alzheimer's Disease

Volumn 35, Issue 1, 2013, Pages 179-198

  Acharya, Nimish K ^a   Levin, Eli C ^a   Clifford, Peter M ^a   Han, Min ^a   Tourtellotte, Ryan ^a   Chamberlain, Dean ^a   Pollaro, Michael ^a   Coretti, Nicholas J ^a   Kosciuk, Mary C ^a   Nagele, Eric P ^a   Demarshall, Cassandra ^a   Freeman, Theresa ^b   Shi, Yi ^b   Guan, Chenbing ^c   MacPhee, Colin H ^d   Wilensky, Robert L ^e   Nagele, Robert G ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (China)

^d GLAXOSMITHKLINE   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; amyloid ; autoantibodies; blood brain barrier; cholesterol; darapladib; diabetes mellitus; immunoglobulin; lipoprotein associated phospholipase A (LpPLA); microvasculature

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; DARAPLADIB; IMMUNOGLOBULIN G;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CONTROLLED STUDY; DIABETES MELLITUS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; QUANTITATIVE ANALYSIS; RAT; SWINE;

EID: 84876355101     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122254     Document Type: Article

References (79)

1. (2012) 2012 Alzheimer's disease facts and figures. Alzheimers Dement 8, 131-168.
2. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
3. Dickson DW (1997) Neuropathological diagnosis of Alzheimer's disease: A perspective from longitudinal clinicopathological studies. Neurobiol Aging 18, S21-S26. (Pubitemid 27454692)
4. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917.
5. Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan InstituteWorking Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56, 1095-1097.
6. Mirra SS, Hart MN, Terry RD (1993) Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med 117, 132-144. (Pubitemid 23057613)
7. Schubert P, OgataT, Marchini C, Ferroni S (2001) Glia-related pathomechanisms in Alzheimer's disease: A therapeutic target? Mech Ageing Dev 123, 47-57. (Pubitemid 32972258)
8. DeKosky ST, Scheff SW(1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464. (Pubitemid 20149963)
9. Allen KV, Frier BM, Strachan MW (2004) The relationship between type 2 diabetes and cognitive dysfunction: Longitudinal studies and their methodological limitations. Eur J Pharmacol 490, 169-175. (Pubitemid 38482170)
10. Awad N, Gagnon M, Messier C (2004) The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 26, 1044-1080. (Pubitemid 39577337)
11. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5, 64-74. (Pubitemid 41790697)
12. Carlsson CM (2010) Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis 20, 711-722.
13. Huber JD (2008) Diabetes, cognitive function, and the bloodbrain barrier. Curr Pharm Des 14, 1594-1600. (Pubitemid 352002986)
14. Taguchi A (2009) Vascular factors in diabetes and Alzheimer's disease. J Alzheimers Dis 16, 859-864.
15. Shepardson NE, Shankar GM, Selkoe DJ (2011) Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 68, 1239-1244.
16. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD (2007) Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: Contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 50, 202-211. (Pubitemid 46035869)
17. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, Sulkava R, Kivipelto M (2010) Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology 75, 1195-1202.
18. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) Risk of dementia among per sons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 145, 301-308. (Pubitemid 27082028)
19. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM (1996) Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 39, 1392-1397. (Pubitemid 26356072)
20. Zambon D, Quintana M, Mata P, Alonso R, Benavent J, Cruz- Sanchez F, Gich J, Pocovi M, Civeira F, Capurro S, Bachman D, Sambamurti K, Nicholas J, Pappolla MA (2010) Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med 123, 267-274.
21. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K (2005) Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study. BMJ 330, 1360.
22. Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59, 378-384. (Pubitemid 34208144)
23. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M (2007) Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study. Neurology 68, 751-756. (Pubitemid 46667900)
24. de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3, 184-190. (Pubitemid 38232669)
25. Breteler MM (2000) Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 903, 457-465. (Pubitemid 30251589)
26. Kalaria RN (2010) Vascular basis for brain degeneration: Faltering controls and risk factors for dementia. Nutr Rev 68(Suppl 2), S74-S87.
27. Thal DR, Grinberg LT, Attems J (2012) Vascular dementia: Different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 47, 816-824.
28. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
29. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, StreitW, Strohmeyer R, Tooyoma I, VanMuiswinkel FL,Veerhuis R,Walker D,Webster S,Wegrzyniak B,Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421. (Pubitemid 30349107)
30. Carrano A, Hoozemans JJ, van der Vies SM, van Horssen J, de Vries HE, Rozemuller AJ (2012) Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis 10, 329-331.
31. Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ (2000) Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 903, 335-344. (Pubitemid 30251574)
32. Sims-Robinson C, Kim B, RoskoA, Feldman EL (2010) How does diabetes accelerate Alzheimerdisease pathology? Nat Rev Neurol 6, 551-559.
33. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37, 13-25.
34. Bowman GL, Kaye JA, Quinn JF (2012) Dyslipidemia and blood-brain barrier integrity in Alzheimer's disease. Curr Gerontol Geriatr Res 2012, 184042.
35. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol 66, 300-305.
36. Gloor SM, Wachtel M, Bolliger MF, Ishihara H, Landmann R, Frei K (2001) Molecular and cellular permeability control at the blood-brain barrier. Brain Res Brain Res Rev 36, 258-264. (Pubitemid 33020756)
37. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
38. Alafuzoff I, Adolfsson R, Grundke-Iqbal I,Winblad B (1985) Perivascular deposits of serum proteins in cerebral cortex in vascular dementia. Acta Neuropathol 66, 292-298. (Pubitemid 15005799)
39. Alafuzoff I, Adolfsson R, Grundke-Iqbal I, Winblad B (1987) Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol 73, 160-166. (Pubitemid 17060012)
40. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V, D'Andrea MR, Dinsmore S, Nagele RG (2007) Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142, 223-236. (Pubitemid 46413194)
41. Mooradian AD (1988) Effect of aging on the blood-brain barrier. Neurobiol Aging 9, 31-39. (Pubitemid 18063330)
42. Nagele RG, Clifford PM, Siu G, Levin EC, Acharya NK, Han M, Kosciuk MC, Venkataraman V, Zavareh S, Zarrabi S, Kinsler K, Thaker NG, Nagele EP, Dash J,Wang HY, Levitas A (2011) Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta (1-42) deposition. J Alzheimers Dis 25, 605-622.
43. Weiss N, Miller F, Cazaubon S, Couraud PO (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788, 842-857.
44. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH(2008) Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 14, 1059-1066.
45. Levin EC, Acharya NK, Han M, Zavareh SB, Sedeyn JC, Venkataraman V, Nagele RG (2010) Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res 1345, 221-232.
46. D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38, 120-134. (Pubitemid 32193626)
47. Nagele RG, D'Andrea MR, Anderson WJ, Wang HY (2002) Intracellular accumulation of beta-amyloid (1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110, 199-211. (Pubitemid 34214939)
48. Onul A, Colvard MD, Paradise WA, Elseth KM, Vesper BJ, Gouvas E, Deliu Z, Garcia KD, Pestle WJ, Radosevich JA (2012) Application of immunohistochemical staining to detect antigen destruction as a measure of tissue damage. J Histochem Cytochem 60, 683-693.
49. Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Hayashi T, Yamaguchi H, Shimohama S, Lee HG, Zhu X, Smith MA, Perry G (2010) Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 37, 731-737.
50. Dumont M, Ho DJ, CalingasanNY,XuH, Gibson G, BealMF (2009) Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radic Biol Med 47, 1019-1027.
51. Mooradian AD (1994) Potential mechanisms of the agerelated changes in the blood-brain barrier. Neurobiol Aging 15, 751-755; discussion 761-752, 767. (Pubitemid 24360167)
52. Moroz N, Tong M, Longato L, Xu H, de la Monte SM (2008) Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 15, 29-44.
53. Jiang X, Guo M, Su J, Lu B, Ma D, Zhang R, Yang L, Wang Q, MaY, FanY(2012) Simvastatin blocks blood-brain barrier disruptions induced by elevated cholesterol both in vivo and in vitro. Int J Alzheimers Dis 2012, 1-7.
54. Luchsinger JA, Gustafson DR (2009) Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16, 693-704.
55. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, Yan JC, Zhou HD (2011) Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76, 1485-1491.
56. Viggars AP,Wharton SB, Simpson JE, Matthews FE, Brayne C, Savva GM, Garwood C, Drew D, Shaw PJ, Ince PG (2011) Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: A study in the MRC-CFASpopulation neuropathology cohort. Neurosci Lett 505, 25-30.
57. Matsuzaki T, Sasaki K, Hata J, Hirakawa Y, Fujimi K, Ninomiya T, Suzuki SO, Kanba S, KiyoharaY, Iwaki T (2011) Association of Alzheimer disease pathology with abnormal lipid metabolism: The Hisayama Study. Neurology 77, 1068-1075.
58. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y (2011) Glucose tolerance status and risk of dementia in the community: The Hisayama study. Neurology 77, 1126-1134.
59. Harris MI (1991) Hypercholesterolemia in diabetes and glucose intolerance in the U.S. population. Diabetes Care 14, 366-374.
60. Buee L, Hof PR, Delacourte A (1997) Brain microvascular changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci 826, 7-24. (Pubitemid 27478027)
61. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66, 343-348.
62. KalariaRN(1996) Cerebral vessels in ageing and Alzheimer's disease. Pharmacol Ther 72, 193-214. (Pubitemid 26425810)
63. Kleine TO, Hackler R, Zofel P (1993) Age-related alterations of the blood-brain-barrier (BBB) permeability to protein molecules of different size. Z Gerontol 26, 256-259. (Pubitemid 23336908)
64. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormickW, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB (2010) Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 58, 1311-1317.
65. Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003) Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463-470. (Pubitemid 39004272)
66. Farrall AJ, Wardlaw JM (2009) Blood-brain barrier: Ageing and microvascular disease - systematic review and metaanalysis. Neurobiol Aging 30, 337-352.
67. Hawkins BT, Davis TP (2005) The blood-brain barrier/ neurovascular unit in health and disease. Pharmacol Rev 57, 173-185. (Pubitemid 41043883)
68. Simpson JE, Wharton SB, Cooper J, Gelsthorpe C, Baxter L, Forster G, Shaw PJ, Savva G, Matthews FE, Brayne C, Ince PG (2010) Alterations of the blood-brain barrier in cerebral white matter lesions in the ageing brain. Neurosci Lett 486, 246-251.
69. Abbott NJ (2000) Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 20, 131-147. (Pubitemid 30091452)
70. Nagele E, Han M, Demarshall C, Belinka B, Nagele R (2011) Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera. PLoS One 6, e23112.
71. Han M, Nagele E, DeMarshall C, Acharya N, NageleR(2012) Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One 7, e32383.
72. de la Torre JC (1997) Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology 43, 26-43. (Pubitemid 27013494)
73. Zhao Y, Liu X, Yu A, Zhou Y, Liu B (2010) Diabetes-related alteration of occludin expression in rat blood-spinal cord barrier. Cell Biochem Biophys 58, 141-145.
74. Klaassen I, Hughes JM, Vogels IM, Schalkwijk CG, Van Noorden CJ, Schlingemann RO (2009) Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes. Exp Eye Res 89, 4-15.
75. Schreibelt G, Kooij G, Reijerkerk A, van Doorn R, Gringhuis SI, van der Pol S, Weksler BB, Romero IA, Couraud PO, Piontek J, Blasig IE, Dijkstra CD, Ronken E, de Vries HE (2007) Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J 21, 3666-3676. (Pubitemid 350075154)
76. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, SchmidtAM(1996)RAGEand amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691. (Pubitemid 26282167)
77. Hartz AM, Bauer B, Soldner EL, Wolf A, Boy S, Backhaus R, Mihaljevic I, Bogdahn U, Klunemann HH, Schuierer G, Schlachetzki F (2012) Amyloid-beta contributes to bloodbrain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 43, 514-523.
78. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM (1999) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor. Biochem J 338(Pt 2), 479-487.
79. Rosenson RS, Stafforini DM (2012) Modulation of oxidative stress, inflammation, and atherosclerosis by lipoproteinassociated phospholipase A2. J Lipid Res 53, 1767-1782.